Graves Diseases - Pipeline Review, H2 2019

December 2019 | 49 pages | ID: G04F78C9678EN
Global Markets Direct

Abstracts

Graves Diseases - Pipeline Review, H2 2019

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Graves Diseases - Pipeline Review, H2 2019, provides an overview of the Graves Diseases (Hormonal Disorders) pipeline landscape.

Graves' disease is an immune system disorder that results in the overproduction of thyroid hormones (hyperthyroidism). Symptoms include anxiety, weight loss, change in menstrual cycles, erectile dysfunction, bulging eyes and irregular heartbeat. Risk factors include family history, age, autoimmune disorders, smoking and pregnancy. Treatment includes anti-thyroid medications, beta blockers and surgery.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Graves Diseases - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Graves Diseases (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Graves Diseases (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Graves Diseases and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 2 and 2 respectively.

Graves Diseases (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Graves Diseases (Hormonal Disorders).
• The pipeline guide reviews pipeline therapeutics for Graves Diseases (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Graves Diseases (Hormonal Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Graves Diseases (Hormonal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Graves Diseases (Hormonal Disorders)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Graves Diseases (Hormonal Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Graves Diseases (Hormonal Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Graves Diseases - Overview
Graves Diseases - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Graves Diseases - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Graves Diseases - Companies Involved in Therapeutics Development
advanceCor GmbH
Apitope International NV
AV7 Ltd
GlaxoSmithKline Plc
Novartis AG
Omeros Corp
Rodos BioTarget GmbH
Virtici LLC
Graves Diseases - Drug Profiles
ATXGD-59 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
belimumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
iscalimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
K-170 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Protein for Graves Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit GPR174 for Immunology, Neurology and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides for Graves Diseases and Graves Ophthalmopathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VTCG-90 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Graves Diseases - Dormant Projects
Graves Diseases - Product Development Milestones
Featured News & Press Releases
Jun 20, 2019: Apitope announces publication of data in international peer-reviewed journal thyroid on Graves’ disease Therapy
Aug 14, 2018: Apitope Announces Publication of Graves’ Disease Data in International Peer-Reviewed Journal, Endocrinology
Apr 16, 2018: Apitope Announces Positive Results with Novel Treatment for Graves Disease
Oct 26, 2016: Apitope Announces Enrolment of First Patient in Phase I Trial of ATX-GD-59 for the Treatment of Graves Disease
Jun 19, 2014: Apitope Progresses Graves' Disease Treatment
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Graves Diseases, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Graves Diseases - Pipeline by advanceCor GmbH, H2 2019
Graves Diseases - Pipeline by Apitope International NV, H2 2019
Graves Diseases - Pipeline by AV7 Ltd, H2 2019
Graves Diseases - Pipeline by GlaxoSmithKline Plc, H2 2019
Graves Diseases - Pipeline by Novartis AG, H2 2019
Graves Diseases - Pipeline by Omeros Corp, H2 2019
Graves Diseases - Pipeline by Rodos BioTarget GmbH, H2 2019
Graves Diseases - Pipeline by Virtici LLC, H2 2019
Graves Diseases - Dormant Projects, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development for Graves Diseases, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Targets, H2 2019
Number of Products by Stage and Targets, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

advanceCor GmbH
Apitope International NV
AV7 Ltd
GlaxoSmithKline Plc
Novartis AG
Omeros Corp
Rodos BioTarget GmbH
Virtici LLC